Christopher Goetz to Dopamine Agents
This is a "connection" page, showing publications Christopher Goetz has written about Dopamine Agents.
Connection Strength
0.607
-
Wearing-off scales in Parkinson's disease: critique and recommendations. Mov Disord. 2011 Oct; 26(12):2169-75.
Score: 0.382
-
A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease. Mov Disord. 2016 09; 31(9):1373-80.
Score: 0.133
-
A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol. 2005 Feb; 57(2):197-203.
Score: 0.061
-
Hallucinations in Parkinson disease in the prelevodopa era. Neurology. 2006 Jan 10; 66(1):93-8.
Score: 0.016
-
Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system. Arch Neurol. 2004 Aug; 61(8):1280-4.
Score: 0.015